The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Metabolic response to enzalutamide (ENZ), assessed by choline positron emission tomography (cPET), in castration resistant prostate cancer (CRPC) patients (pts): Updated results of a monoinstitutional prospective study.
Francesca Maines
No relevant relationships to disclose
Orazio Caffo
No relevant relationships to disclose
Davide Donner
No relevant relationships to disclose
Antonello Veccia
No relevant relationships to disclose
Franca Chierichetti
No relevant relationships to disclose
Enzo Galligioni
No relevant relationships to disclose